| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2011 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DELTA AIR LINES INC DEL | 41 | Q2 2024 | 25.1% |
| EATON CORP PLC | 36 | Q2 2024 | 11.6% |
| TAIWAN SEMICONDUCTOR MFG LTD | 28 | Q2 2024 | 30.1% |
| AMAZON COM INC | 24 | Q2 2024 | 13.9% |
| MANCHESTER UTD PLC NEW | 22 | Q3 2019 | 1.0% |
| SUMMIT THERAPEUTICS PLC | 22 | Q2 2020 | 0.6% |
| JPMORGAN CHASE & CO | 20 | Q1 2019 | 19.9% |
| CITIGROUP INC | 20 | Q4 2020 | 12.2% |
| FIRST SOLAR INC | 20 | Q3 2021 | 4.2% |
| UNITED TECHNOLOGIES CORP | 20 | Q1 2020 | 3.7% |
View LANSDOWNE PARTNERS (UK) LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Soho House & Co Inc. | February 13, 2024 | 2,619,141 | 4.9% |
| Supernova Partners Acquisition Co II, Ltd. | February 14, 2022 | 2,152,911 | 6.2% |
| Summit Therapeutics plc | June 17, 2020 | 13,664,880 | 4.1% |
| Manchester United plcSold out | February 14, 2020 | 0 | 0.0% |
| CYTOKINETICS INC | January 30, 2018 | 2,647,981 | 4.9% |
| RESPONSE GENETICS INCSold out | February 12, 2016 | 0 | 0.0% |
View LANSDOWNE PARTNERS (UK) LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| SC 13G | 2023-02-08 |
View LANSDOWNE PARTNERS (UK) LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.